2022 Q1 Report Released -Wondfo, BGI, Leadman, Sinocare, ACROBiosystems, NanoMicro

In the first quarter of 2022, Wondfo Biotech achieved operating income of CNY 2.625 billion, a year-on-year increase of 276.87%; net profit attributable to the parent was CNY 904 million, a year-on-year increase of 481.32%.

The operating income of BGI in the first quarter of 2022 was CNY 1.43 billion, a year-on-year decrease of 8.52%; the net profit attributable to the parent was CNY 330 million, a year-on-year decrease of 37.06%.

In the first quarter of 2022, Sinocare achieved operating income of CNY 619 million, a year-on-year increase of 23.27%; net profit attributable to the parent was CNY 65.2933 million, a year-on-year increase of 45.22%.

Leadman achieved operating income of CNY 192 million in the first quarter of 2022, a year-on-year increase of 65.55%; net profit attributable to the parent was CNY 12.1091 million, a year-on-year increase of 93.14%.

In the first quarter of 2022, ACROBiosystems achieved operating income of CNY 110 million, a year-on-year increase of 27.7%; net profit attributable to the parent was CNY 53.501 million, a year-on-year increase of 31.66%.

In the first quarter of 2022, NanoMicro achieved a total operating income of CNY 140 million, a year-on-year increase of 111.7%; net profit attributable to the parent was CNY 60.924 million, a year-on-year increase of 176.2%.